The Journal of Practical Medicine ›› 2024, Vol. 40 ›› Issue (16): 2224-2228.doi: 10.3969/j.issn.1006-5725.2024.16.005

• Symposiums • Previous Articles     Next Articles

Serological biomarkers for diagnosis of diabetes foot: A review of literature

Kaming YANG1,Zhenlin LI1,Wanwen LAO1,Aixia ZHAI2,Changlong. BI1()   

  1. *.Department of Endocrinology,the Eighth Affiliated Hospital,Sun Yat?sen University,Shenzhen 518033,China
  • Received:2024-02-21 Online:2024-08-25 Published:2024-08-26
  • Contact: Changlong. BI E-mail:BCL163@163.com

Abstract:

Diabetic foot (DF), a primary chronic complication of diabetes mellitus, contributes to a major disability and mortality in diabetic patients. DF is diagnosed mainly depending not only on clinical manifestations, signs, and related inspection, but also on recently emerging diagnostic means: biological markers. Inflammatory biomarkers are preferably used for its superiority in DF early diagnosis. In recently years, thanks to advancements of biological technologies, biomarkers such as procalcitonin (PCT), C?reactive protein (CRP), interleukins (ILs), and tumor necrosis factor?alpha (TNF?α) have been comprehensively used in DF diagnosis. Moreover, biomarkers of genomics, proteomics, metabolomics, and metagenomics have been employed as well. In this review, we aim to comprehensively review the role of serum biomarkers in DF diagnosis and risk stratification, elaborating on the current research status in applying serum biomarkers for DF prevention, diagnosis, and prognosis assessment.

Key words: diabetic foot, diagnostic marker, serological biomarkers

CLC Number: